Breaking: Leerink Swann Reaffirms $22 TP On Epizyme (NASDAQ:EPZM) Shares, Reaffirms Their Original Outperform Rating

November 15, 2017 - By Winifred Garcia

 Breaking: Leerink Swann Reaffirms $22 TP On Epizyme (NASDAQ:EPZM) Shares, Reaffirms Their Original Outperform Rating

Investors sentiment increased to 1.93 in 2017 Q2. Its up 0.87, from 1.06 in 2017Q1. It is positive, as 13 investors sold Epizyme Inc shares while 17 reduced holdings. 25 funds opened positions while 33 raised stakes. 47.46 million shares or 3.38% more from 45.91 million shares in 2017Q1 were reported.

Cqs Cayman Limited Partnership holds 614,300 shares. Ghost Tree Capital Ltd Liability, New York-based fund reported 150,000 shares. Oracle Invest Mngmt invested in 292,380 shares. California State Teachers Retirement Systems invested 0% in Epizyme Inc (NASDAQ:EPZM). 32,291 were accumulated by Strs Ohio. Manufacturers Life Insurance The stated it has 33,137 shares or 0% of all its holdings. Boothbay Fund Lc has 0.05% invested in Epizyme Inc (NASDAQ:EPZM). Macquarie Limited reported 20,000 shares. Sg Americas Lc owns 0% invested in Epizyme Inc (NASDAQ:EPZM) for 13,364 shares. Legal & General Public Ltd Co holds 0% or 9,684 shares. Tekla Capital Limited Liability Com stated it has 281,000 shares. Principal Financial Group Inc Inc accumulated 95,572 shares. Moreover, Price T Rowe Assocs Md has 0% invested in Epizyme Inc (NASDAQ:EPZM) for 14,712 shares. Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 988 shares. Dekabank Deutsche Girozentrale stated it has 33,300 shares.

Since May 25, 2017, it had 0 buys, and 2 insider sales for $275,289 activity. $33,625 worth of Epizyme Inc (NASDAQ:EPZM) was sold by Copeland Robert A.

Epizyme (NASDAQ:EPZM) Rating Reaffirmed

Leerink Swann now has a $22 target on shares of Epizyme (NASDAQ:EPZM). The target would suggest a potential upside of 73.91 % from the current price of Epizyme (NASDAQ:EPZM). This rating was disclosed to clients in analysts report on 2 November.

Investors sentiment increased to 1.93 in 2017 Q2. Its up 0.87, from 1.06 in 2017Q1. It is positive, as 13 investors sold Epizyme Inc shares while 17 reduced holdings. 25 funds opened positions while 33 raised stakes. 47.46 million shares or 3.38% more from 45.91 million shares in 2017Q1 were reported.

Cqs Cayman Limited Partnership holds 614,300 shares. Ghost Tree Capital Ltd Liability, New York-based fund reported 150,000 shares. Oracle Invest Mngmt invested in 292,380 shares. California State Teachers Retirement Systems invested 0% in Epizyme Inc (NASDAQ:EPZM). 32,291 were accumulated by Strs Ohio. Manufacturers Life Insurance The stated it has 33,137 shares or 0% of all its holdings. Boothbay Fund Lc has 0.05% invested in Epizyme Inc (NASDAQ:EPZM). Macquarie Limited reported 20,000 shares. Sg Americas Lc owns 0% invested in Epizyme Inc (NASDAQ:EPZM) for 13,364 shares. Legal & General Public Ltd Co holds 0% or 9,684 shares. Tekla Capital Limited Liability Com stated it has 281,000 shares. Principal Financial Group Inc Inc accumulated 95,572 shares. Moreover, Price T Rowe Assocs Md has 0% invested in Epizyme Inc (NASDAQ:EPZM) for 14,712 shares. Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 988 shares. Dekabank Deutsche Girozentrale stated it has 33,300 shares.

Since May 25, 2017, it had 0 buys, and 2 insider sales for $275,289 activity. $33,625 worth of Epizyme Inc (NASDAQ:EPZM) was sold by Copeland Robert A.

Epizyme Inc (NASDAQ:EPZM) Ratings Coverage

Among 11 analysts covering Epizyme (NASDAQ:EPZM), 10 have Buy rating, 0 Sell and 1 Hold. Therefore 91% are positive. Epizyme has $42 highest and $17 lowest target. $23.80’s average target is 88.14% above currents $12.65 stock price. Epizyme had 28 analyst reports since August 6, 2015 according to SRatingsIntel. RBC Capital Markets maintained the stock with “Buy” rating in Thursday, September 14 report. The company was maintained on Wednesday, June 7 by Cowen & Co. JMP Securities maintained Epizyme Inc (NASDAQ:EPZM) rating on Wednesday, March 9. JMP Securities has “Market Outperform” rating and $28 target. As per Monday, September 28, the company rating was maintained by RBC Capital Markets. RBC Capital Markets downgraded the shares of EPZM in report on Thursday, November 2 to “Sector Perform” rating. SunTrust maintained Epizyme Inc (NASDAQ:EPZM) on Friday, October 27 with “Buy” rating. The firm has “Buy” rating given on Tuesday, May 10 by Mizuho. Oppenheimer maintained the shares of EPZM in report on Wednesday, June 14 with “Buy” rating. On Tuesday, August 1 the stock rating was maintained by Oppenheimer with “Buy”. RBC Capital Markets maintained Epizyme Inc (NASDAQ:EPZM) rating on Friday, August 4. RBC Capital Markets has “Buy” rating and $2000 target.

About 10,526 shares traded. Epizyme Inc (NASDAQ:EPZM) has risen 91.85% since November 15, 2016 and is uptrending. It has outperformed by 75.15% the S&P500.

Analysts expect Epizyme Inc (NASDAQ:EPZM) to report $-0.57 EPS on March, 8.They anticipate $0.03 EPS change or 5.00 % from last quarter’s $-0.6 EPS. After having $-0.63 EPS previously, Epizyme Inc’s analysts see -9.52 % EPS growth.

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $876.43 million. The Firm discovers, develops and plans to commercialize epigenetic therapies for cancer patients. It currently has negative earnings. The Firm is engaged in the discovery and development of novel epigenetic therapies for cancer patients.

More recent Epizyme Inc (NASDAQ:EPZM) news were published by: Globenewswire.com which released: “Epizyme to Present at the Jefferies 2017 London Healthcare Conference” on November 01, 2017. Also Globenewswire.com published the news titled: “Epizyme Reports Third Quarter 2017 Operating Results and Company Updates” on November 01, 2017. Globenewswire.com‘s news article titled: “Epizyme Announces Date of Third Quarter 2017 Financial Results” with publication date: October 25, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.